The Center Advisory Committee (CAC) was established by the CRC's Director and co-Director and approved by NIH program officials. The current CAC is comprised of eight members with scientific and clinical expertise and includes patient advocate representation. None of the CAC members are investigators in this Center.
UMMS Wellstone Center Advisory Committee (2014)
Michael R. Altherr, Ph.D.
Mail Stop M888
Los Alamos National Laboratory
Los Alamos, NM 87545
Expert in FSHD and human genetics
Victor Ambrose, Ph.D.
Professor, Program in Molecular Medicine
University of Massachussetts Medical School
373 Plantation Street
Worcester, MA 01655
Expert in complex genetics and RNA therapeutics
Haig Kazazian, M.D.
Professor of Human Genetics
Johns Hopkins University School of Medicine
733 N. Broadway
Baltimore, MD 21205
Expert in human genetics, genome biology and transposable DNA elements
Elizabeth McNally, M.D., Ph.D.
AJ Carson Professor of Medicine & Human Genetics,
Director Institute for Cardiovascular Researcher and Director, Cardiovascular Genetics Clinic
University of Chicago Medical Center
5841 S. Maryland Avenue, MC 6088
Chicago, IL 60637
Expert in muscular dystrophy, mouse models and genetics
Bill Moss, A.M.
Chairman of Moss Capital
Founder of the FSHD Global Research Foundation Limited
FSHD Global Research Foundation Limited
PO Box A298
Leader in FSHD patient advocacy
Terrance Partridge, Ph.D.
Associate Director, Children’s Research Institute
Center for Genetic Medicine Research
Children's National Medical Center
111 Michigan Avenue, NW
Washington, DC 20010-2970
Expert in muscle regeneration and disease
Jude Samulski, Ph.D.
Director of Gene Therapy Center & Professor of Pharmacology
University of North Carolina at Chapel Hill
7119 Thurston Building
Campus Box 7352
Chapel Hill, NC 27599-7352
Expert in gene therapy and muscle disease
Charles Thornton, M.D.
Professor, Department of Neurology
University of Rochester Medical School
School of Medicine and Dentistry
601 Elmwood Ave, Box 645
Rochester, NY 14642
Expert in myotonic dystrophy and RNA therapeutics